Genmab AS ADR (GMAB)

Genmab A/S ADR is a NASDAQ-listed depositary receipt representing common stock of Genmab A/S, a biotechnology company based in Copenhagen, Denmark. The company develops antibody-based medicines and product candidates for cancer and other serious diseases. Its marketed products include EPKINLY and TEPKINLY for certain relapsed or refractory B-cell lymphomas, and Tivdak for recurrent or metastatic cervical cancer after chemotherapy. Genmab is also advancing a pipeline that includes Epcoritamab, tisotumab vedotin, Acasunlimab, Rinatabart Sesutecan, GEN1059, GEN1055, GEN1057, and GEN1286 across multiple oncology indications, as well as programs such as Amlenetug, Inclacumab, and Mim8 in other disease areas. In addition, it has collaborations with several pharmaceutical and biotechnology companies, including AbbVie, Pfizer, BioNTech, Johnson & Johnson, Bristol Myers Squibb, Lundbeck, Amgen, Novo Nordisk, and argenx.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-GMAB
$50.40
-1.9% Downside
Fair
$65.10
26.7% Upside
Undervalued
Great
0.0%
February 24, 2027
44.1x
5.1x
7.5x
32.182 B
35.411 B
13.6%
93.1%
14.1
116.7%
Valuation • Fair Value

Genmab AS ADR (NASDAQ-GMAB) Fair Value by Valuation Model

Review the available estimates for Genmab AS ADR (NASDAQ-GMAB), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$50.40

Estimated downside of 1.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$56.82

Discounted cash flow valuation reference.

Ben Graham Formula Value

$12.79

Classic Ben Graham valuation formula reference.

EPV Fair Value

$28.90

Earnings power value estimate.

Comps Fair Value

$47.58

Comparable-company valuation reference.

Analyst Price Target

$65.10

Analysts imply upside of 26.7%.

How to read these valuation models

Use the 7 available valuation references for Genmab AS ADR (NASDAQ-GMAB) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Genmab AS ADR (NASDAQ-GMAB)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

4.296 B

Current operating scale indicator.

Revenue Forecast

4.485 B

Forward revenue estimate.

EBITDA

1.356 B

Current operating profitability reference.

EBITDA Forecast

1.31 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Genmab AS ADR (NASDAQ-GMAB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Genmab AS ADR (NASDAQ-GMAB)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-2.82

No elevated caution signal from this screen.

Altman Z-Score

14.1

Relatively strong balance-sheet zone.

FCF / Net Income

116.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Genmab AS ADR (NASDAQ-GMAB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Genmab AS ADR (NASDAQ-GMAB)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

February 24, 2027

Days to Earnings

103

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Genmab AS ADR (NASDAQ-GMAB), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Genmab AS ADR (NASDAQ-GMAB) Stock Forecast & Technical Outlook

Review Genmab AS ADR (NASDAQ-GMAB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Genmab AS ADR (NASDAQ-GMAB) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Genmab AS ADR (NASDAQ-GMAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Genmab AS ADR (NASDAQ-GMAB) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Genmab AS ADR (NASDAQ-GMAB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Genmab AS ADR (NASDAQ-GMAB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Genmab AS ADR (NASDAQ-GMAB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Genmab AS ADR (NASDAQ-GMAB) has a Strong Buy consensus, with 9 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 9
Hold 2
Sell 0
FAQ • Fast Investor Answers

Genmab AS ADR (NASDAQ-GMAB) Stock FAQ

Data-supported answers about Genmab AS ADR (NASDAQ-GMAB), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$50.40
Estimated downside 1.9%
Valuation Rating
Near Fair Value
Price is close to fair value
Analyst Target
$65.10
Implied upside 26.7%
Financial Health
Great
Current financial-health read

The current fair value estimate for Genmab AS ADR (NASDAQ-GMAB) is $50.40. This implies an estimated downside of 1.9% versus the current market price.

Based on the current fair value estimate, the stock is trading close to its estimated fair value.

The available analyst price target for Genmab AS ADR (NASDAQ-GMAB) is $65.10. The analyst target implies estimated upside of 26.7%.

The current financial health read for Genmab AS ADR (NASDAQ-GMAB) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Genmab AS ADR (NASDAQ-GMAB) is February 24, 2027.

The latest available data indicates no current dividend yield for Genmab AS ADR (NASDAQ-GMAB).

The current P/E ratio listed for Genmab AS ADR (NASDAQ-GMAB) is 44.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Genmab AS ADR is 32.182 B.

The current enterprise value listed for Genmab AS ADR is 35.411 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Genmab AS ADR is NASDAQ-GMAB, and the stock is listed on NASDAQ.

Genmab AS ADR (NASDAQ-GMAB) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Genmab AS ADR is 13.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Genmab AS ADR is 93.1%. Free float helps investors understand how much of the share base is available for public trading.